查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
无菌注射合同製造市场规模、份额、趋势分析报告：按分子类型、给药途径、治疗用途、最终用途、地区和细分市场预测，2023-2030 年
市场调查报告书
商品编码
1321481

无菌注射合同製造市场规模、份额、趋势分析报告：按分子类型、给药途径、治疗用途、最终用途、地区和细分市场预测，2023-2030 年

Sterile Injectable Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type, By Route Of Administration, By Therapeutic Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10个工作天内

价格

无菌注射剂合同製造市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球无菌注射剂合同製造市场规模将达到 319.2 亿美元，2023 年至 2030 年年复合成长率为 12.1%。

无菌注射剂合同製造行业的推动因素包括注射剂管道和批准的增加、对生物製剂和生物仿製药的需求增加、开发新疗法的研发活动投资增加以及对细胞和基因治疗的需求要素。生长。无菌注射剂的合同製造市场较为分散，多家公司拥有相似的技术和加工能力。

具有管理高效价药物等独特能力的合同製造组织（CMO）预计将主导该行业。欧洲和美国有各种无菌注射剂 CMO，拥有欧盟 GMP 和美国FDA 批准的设施。此外，印度和中国等新兴经济体预计在预测期内将出现良好的增长。这是由于这些国家对注射药品采购服务的需求不断增加。印度有 20 多家获得欧盟 GMP/美国FDA 注射剂认证的 CMO。由于製药巨头对新兴市场具有成本效益的外包服务的需求不断增加，印度的无菌注射剂合同製造行业正在迅速扩张。儘管印度大多数注射剂 CMO 一直在迎合当地需求，但近年来这种转变已变得明显。

COVID-19 大流行对无菌注射剂合同製造行业产生了积极影响。这是由于 2020 年至 2021 年对 COVID-19 疫苗的需求大幅增加。市场上的主要参与者也正在采用合併、收购和联盟等无机战略倡议来增强其市场地位。此外，近年来，多家公司专注于进入註射剂合同製造行业。例如，全球私人投资公司 Bridgewest Group 宣布推出专注于无菌注射剂的新受託製造厂商(CDMO) 设施。

无菌注射合同製造市场报告亮点

  • 2022年，大分子细分市场将占据最大份额，达到61.3%。该领域的增长是由对大分子治疗的需求不断增长推动的，包括细胞和基因治疗以及 RNA 治疗，它们占大分子的大部分。
  • 按治疗用途来看，癌症领域占比最大，2022年将达到28.5%。该细分市场份额的增加主要是由于对基于抗癌药物的注射疗法的需求增加。
  • 皮下 (SC) 领域预计在预测期内年复合成长率最快，达到 12.6%。这是因为皮下注射剂由于与註射疫苗、生长激素和胰岛素相关的益处而在全球范围内需求量很大。
  • 随着越来越多的生物製药公司投资开发新型无菌注射剂，预计生物製药公司在预测期内的年复合成长率将达到 12.4%。
  • 亚太地区预计在预测期内復合年复合成长率高达 13.1%。这种高增长主要是由于越来越多的西方製药公司将其製造业务外包给印度和中国等新兴经济体。

目录

第1章调查方法和范围

第2章执行摘要

第3章无菌注射合同製造市场变量、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/辅助市场预测
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 无菌注射合同製造市场分析工具
    • 行业分析-搬运工
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第4章无菌注射剂合同製造市场：分子类型估计和趋势分析

  • 无菌注射合同製造市场，按分子类型：细分仪表板
  • 按分子类型分類的无菌注射合同製造市场：波动分析
    • 低分子
    • 高分子

第5章无菌注射剂合同製造市场：治疗用途的估计和趋势分析

  • 无菌注射剂合同製造市场（按治疗用途）：细分仪表板
  • 无菌注射剂合同製造市场，按治疗用途划分：波动分析
    • 癌症
    • 糖尿病
    • 心血管疾病
    • 中枢神经系统疾病
    • 感染疾病
    • 肌肉骨骼系统
    • 抗病毒药
    • 其他的

第6章无菌注射剂合同製造市场：给药途径预估及趋势分析

  • 无菌注射合同製造市场（按管理途径）：细分仪表板
  • 无菌注射剂合同製造市场，按管理途径：波动分析
    • 皮下注射（SC）
    • 静脉注射(IV)
    • 肌内註射 (IM)
    • 其他的

第7章无菌注射合同製造市场：最终用途估计和趋势分析

  • 无菌注射合同製造市场（按最终用途）：细分仪表板
  • 按最终用途的无菌注射合同製造市场：波动分析
    • 製药公司
    • 生物製药公司
    • 其他的

第8章无菌注射剂合同製造市场：区域估计和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 北美
    • 2018-2030 年市场估计和预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳大利亚
    • 泰国
  • 拉美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第9章竞争形势

  • 市场参与企业分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2022 年公司市场份额分析
  • 公司简介
    • Baxter
    • Catalent, Inc
    • Vetter Pharma
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi
    • Unither Pharmaceuticals
    • Famar
    • Cipla Inc.
    • NextPharma Technologies
Product Code: GVR-4-68040-097-0

Sterile Injectable Contract Manufacturing Market Growth & Trends

The global sterile injectable contract manufacturing market size is estimated to reach USD 31.92 billion by 2030, growing at a CAGR of 12.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing pipeline and approvals of injectables, growing demand for biologics and biosimilars, rise in investment in research & development activities for the development of novel therapeutics, and increasing demand for cell & gene therapies are the key factors driving the growth of sterile injectable contract manufacturing industry. The market for sterile injectable contract manufacturing is fragmented, with several players having similar technological and processing capabilities.

Contract Manufacturing Organizations (CMOs) with unique capabilities, such as the management of high-potency drugs, are anticipated to dominate the industry. In Europe and the U.S., there are various sterile injectable CMOs with EU GMP and U.S. FDA-approved facilities. Moreover, developing economies such as India and China are anticipated to witness lucrative growth across the forecast period. This is attributable to the increasing demand for injectable sourcing services across these countries. India has over 20 CMOs with EU GMP/U.S. FDA injectable certifications. The Indian sterile injectable contract manufacturing industry is rapidly expanding due to rising demand for outsourcing services from the pharmaceutical giants to emerging markets for cost-effectiveness. Most Indian injectable CMOs have been catering to local demand, but the transition has been evident over the past few years.

The COVID-19 pandemic positively impacted the sterile injectable contract manufacturing industry. This was because of the huge surge in demand for COVID-19 vaccines from 2020 to 2021, as these vaccines are a major part of the injectables industry. In addition, major players in the market are adopting inorganic strategic initiatives such as mergers, acquisitions, and partnerships to enhance their market positions. Furthermore, for the past few years, several companies have focused on penetrating the injectable contract manufacturing industry. For instance, Bridgewest Group, a global private investment firm, announced the launch of a new contract development and manufacturing organization (CDMO) facility focused on sterile injectable drug products.

Sterile Injectable Contract Manufacturing Market Report Highlights

  • The large molecule segment accounted for the largest share of 61.3% in 2022. The segment's growth is driven by increasing demand for large molecule-based therapeutics such as cell & gene therapy, RNA therapy, etc., which constitute a vast portion of large molecules
  • Based on therapeutic application, the cancer segment accounted for the largest share of 28.5% in 2022. The growth in the share of this segment is majorly due to the increasing demand for anti-cancer-based injectable therapeutics
  • The Subcutaneous (SC) segment is anticipated to register the fastest CAGR of 12.6% during the forecast period. This is because of the high demand for SC injectables globally, owing to their associated benefits while administering vaccines, growth hormones, and insulin
  • Biopharmaceutical companies are anticipated to witness the highest CAGR of 12.4% over the forecast period due to the increasing number of biopharmaceutical companies investing in developing novel sterile injectables
  • Asia Pacific is anticipated to witness the highest CAGR of 13.1% during the forecast period. This high growth is primarily due to the increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as India and China

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Molecule Type
    • 1.1.3. Therapeutic Application
    • 1.1.4. Route of Administration
    • 1.1.5. End-use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Sterile Injectable Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics.
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Sterile Injectable Contract Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Sterile Injectable Contract Manufacturing Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Sterile Injectable Contract Manufacturing Market, By Molecule Type: Segment Dashboard
  • 4.2. Sterile Injectable Contract Manufacturing Market, By Molecule Type: Movement Analysis
  • 4.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Molecule Type, 2018 - 2030
    • 4.3.1. Small Molecule
      • 4.3.1.1. Small Molecule Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 4.3.2. Large Molecule
      • 4.3.2.1. Large Molecule Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectable Contract Manufacturing Market: Therapeutic Application Estimates & Trend Analysis

  • 5.1. Sterile Injectable Contract Manufacturing Market, By Therapeutic Application: Segment Dashboard
  • 5.2. Sterile Injectable Contract Manufacturing Market, By Therapeutic Application: Movement Analysis
  • 5.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Therapeutic Application, 2018 - 2030
    • 5.3.1. Cancer
      • 5.3.1.1. Cancer Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.2. Diabetes
      • 5.3.2.1. Diabetes Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.3. Cardiovascular Diseases
      • 5.3.3.1. Cardiovascular Diseases Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.4. Central Nervous System Diseases
      • 5.3.4.1. Central Nervous System Diseases Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.5. Infectious Disorders
      • 5.3.5.1. Infectious Disorders Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.6. Musculoskeletal
      • 5.3.6.1. Musculoskeletal Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.7. Anti-Viral
      • 5.3.7.1. Anti-Viral Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)
    • 5.3.8. Others
      • 5.3.8.1. Others Sterile Injectable Contract Manufacturing Market, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectable Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Sterile Injectable Contract Manufacturing Market, By Route of Administration: Segment Dashboard
  • 6.2. Sterile Injectable Contract Manufacturing Market, By Route of Administration: Movement Analysis
  • 6.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
    • 6.3.1. Subcutaneous (SC)
      • 6.3.1.1. Subcutaneous (SC) Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)
    • 6.3.2. Intravenous (IV)
      • 6.3.2.1. Intravenous (IV) Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)
    • 6.3.3. Intramuscular (IM)
      • 6.3.3.1. Intramuscular (IM) Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)
    • 6.3.4. Others
      • 6.3.4.1. Others Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectable Contract Manufacturing Market: End-use Estimates & Trend Analysis

  • 7.1. Sterile Injectable Contract Manufacturing Market, By End-use: Segment Dashboard
  • 7.2. Sterile Injectable Contract Manufacturing Market, By End-use: Movement Analysis
  • 7.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By End-use, 2018 - 2030
    • 7.3.1. Pharmaceutical Companies
      • 7.3.1.1. Pharmaceutical Companies Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)
    • 7.3.2. Biopharmaceutical Companies
      • 7.3.2.1. Biopharmaceutical Companies Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Sterile Injectable Contract Manufacturing Market 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectable Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2022 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Competitive Scenario
      • 8.5.1.3. Regulatory Framework
      • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 8.5.2. Germany
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. France
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. Italy
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Spain
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Denmark
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Norway
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key Country Dynamics
      • 8.6.1.2. Competitive Scenario
      • 8.6.1.3. Regulatory Framework
      • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 8.6.2. India
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. South Korea
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. Thailand
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key Country Dynamics
      • 8.7.1.2. Competitive Scenario
      • 8.7.1.3. Regulatory Framework
      • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 8.7.2. Mexico
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key Country Dynamics
      • 8.8.1.2. Competitive Scenario
      • 8.8.1.3. Regulatory Framework
      • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. UAE
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. Kuwait
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
    • 9.1.4. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. Baxter
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Service Benchmarking
      • 9.2.1.4. Strategic Initiatives
    • 9.2.2. Catalent, Inc
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Service Benchmarking
      • 9.2.2.4. Strategic Initiatives
    • 9.2.3. Vetter Pharma
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Service Benchmarking
      • 9.2.3.4. Strategic Initiatives
    • 9.2.4. Recipharm AB
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Service Benchmarking
      • 9.2.4.4. Strategic Initiatives
    • 9.2.5. Aenova Group
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Financial Performance
      • 9.2.5.3. Service Benchmarking
      • 9.2.5.4. Strategic Initiatives
    • 9.2.6. Fresenius Kabi
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Service Benchmarking
      • 9.2.6.4. Strategic Initiatives
    • 9.2.7. Unither Pharmaceuticals
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Service Benchmarking
      • 9.2.7.4. Strategic Initiatives
    • 9.2.8. Famar
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Financial Performance
      • 9.2.8.3. Service Benchmarking
      • 9.2.8.4. Strategic Initiatives
    • 9.2.9. Cipla Inc.
      • 9.2.9.1. Company Overview
      • 9.2.9.2. Financial Performance
      • 9.2.9.3. Service Benchmarking
      • 9.2.9.4. Strategic Initiatives
    • 9.2.10. NextPharma Technologies
      • 9.2.10.1. Company Overview
      • 9.2.10.2. Financial Performance
      • 9.2.10.3. Service Benchmarking
      • 9.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Sterile Injectable Contract Manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 5 North America Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 6 North America Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 U.S. Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 12 Canada Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 13 Canada Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 16 Europe Sterile Injectable Contract Manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Europe Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 21 UK Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 22 UK Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 23 UK Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 25 Germany Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Germany Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 29 France Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 30 France Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 31 France Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 France Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 33 Italy Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 34 Italy Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Italy Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 37 Spain Sterile Injectable Contract Manufacturing market, by Therapeutic Application type, 2018 - 2030 (USD Million)
  • Table 38 Spain Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Spain Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 41 Denmark Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 42 Denmark Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 43 Denmark Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 45 Sweden Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 46 Sweden Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 47 Sweden Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Sweden Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 49 Norway Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 50 Norway Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 51 Norway Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Norway Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Sterile Injectable Contract Manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 58 China Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 59 China Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 60 China Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 China Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 62 Japan Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 63 Japan Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 64 Japan Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Japan Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 66 India Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 67 India Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 68 India Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 India Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 70 Australia Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 71 Australia Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 72 Australia Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Australia Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 74 South Korea Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 75 South Korea Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 76 South Korea Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 77 South Korea Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 78 Thailand Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 79 Thailand Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 80 Thailand Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 Thailand Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 82 Latin America Sterile Injectable Contract Manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 83 Latin America Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 84 Latin America Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 85 Latin America Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Latin America Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 87 Brazil Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 88 Brazil Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 89 Brazil Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Brazil Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 91 Mexico Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 92 Mexico Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 93 Mexico Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Mexico Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 95 Argentina Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 96 Argentina Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 97 Argentina Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 Argentina Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Sterile Injectable Contract Manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 104 South Africa Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 105 South Africa Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 106 South Africa Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 107 South Africa Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 112 UAE Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 113 UAE Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 114 UAE Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 115 UAE Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Sterile Injectable Contract Manufacturing market, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Sterile Injectable Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Sterile Injectable Contract Manufacturing market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Sterile Injectable Contract Manufacturing market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Sterile Injectable Contract Manufacturing market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Sterile Injectable Contract Manufacturing Market Molecule Type outlook: Segment dashboard
  • Fig. 26 Sterile Injectable Contract Manufacturing: Molecule Type movement analysis
  • Fig. 27 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 28 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 29 Sterile Injectable Contract Manufacturing Market Therapeutic Application outlook: Segment dashboard
  • Fig. 30 Sterile Injectable Contract Manufacturing: Therapeutic Application type movement analysis
  • Fig. 31 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 32 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiovascular Diseases market, 2018 - 2030 (USD Million)
  • Fig. 34 Central Nervous System Diseases market, 2018 - 2030 (USD Million)
  • Fig. 35 Infectious Disorders market, 2018 - 2030 (USD Million)
  • Fig. 36 Musculoskeletal market, 2018 - 2030 (USD Million)
  • Fig. 37 Anti-Viral market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Sterile Injectable Contract Manufacturing market Route of Administration outlook: Segment dashboard
  • Fig. 40 Sterile Injectable Contract Manufacturing market: Route of Administration movement analysis
  • Fig. 41 Subcutaneous (SC) market, 2018 - 2030 (USD Million)
  • Fig. 42 Intravenous (IV) market, 2018 - 2030 (USD Million)
  • Fig. 43 Intramuscular (IM) market, 2018 - 2030 (USD Million)
  • Fig. 44 Regional marketplace: Segment dashboard
  • Fig. 45 Regional outlook, 2022 & 2030
  • Fig. 46 North America market, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 48 Canada market, 2018 - 2030 (USD Million)
  • Fig. 49 Europe market, 2018 - 2030 (USD Million)
  • Fig. 50 Germany market, 2018 - 2030 (USD Million)
  • Fig. 51 UK market, 2018 - 2030 (USD Million)
  • Fig. 52 France market, 2018 - 2030 (USD Million)
  • Fig. 53 Italy market, 2018 - 2030 (USD Million)
  • Fig. 54 Spain market, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark market, 2018 - 2030(USD Million)
  • Fig. 56 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 57 Norway market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 59 China market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan market, 2018 - 2030 (USD Million)
  • Fig. 61 India market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia market, 2018 - 2030 (USD Million)
  • Fig. 63 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 66 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait market, 2018 - 2030 (USD Million)